AR065983A1 - Derivados de furo [2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 - Google Patents
Derivados de furo [2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1Info
- Publication number
- AR065983A1 AR065983A1 ARP080101449A ARP080101449A AR065983A1 AR 065983 A1 AR065983 A1 AR 065983A1 AR P080101449 A ARP080101449 A AR P080101449A AR P080101449 A ARP080101449 A AR P080101449A AR 065983 A1 AR065983 A1 AR 065983A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- unsubstituted
- substituents
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la que: R1 se selecciona a partir de: fenilo, heteroarilo, -C(O)Ra, -C(O)ORa, -C(O)NRbRc, y -S(O)2Ra, en la que cada fenilo y heteroarilo está insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH, -alquilo C1-6, y halogeno, y en la que Rb y Rc junto con los átomos alos que están unidos pueden formar un anillo monocíclico o bicíclico, aromático o no aromático de 4-10 miembros, en el que el anillo de 4-10 miembros está insustituido o sustituido con de uno a cuarto sustituyentes que se seleccionanindependientemente a partir de -OH, -alquilo C1-6, y halogeno; R2 se selecciona a partir de alquilo C1-10, cicloalquilo C3-10, cicloheteroalquilo, feniIo, heteroarilo, -C(O)alquilo C1-10, -C(O)ORa, -C(O)N(Rb)2-, -N(Rb)2, y -NRdC(O)alquilo C1-10, enla que cada alquilo, cicloalquilo, cicloheteroalquilo, fenilo y heteroarilo esta insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH, alquilo C1-6, y oxo; R3 se selecciona a partir dehidrogeno, alquilo C1-10, halogeno, -CN, -CF3, -OCF3, -C(O)alquilo C1-4, -C(O)O-alquilo C1-4, -O-alquilo C1-4, y -S-alquilo C1-4; R4 se selecciona a partir de: pirazol, oxadiazol, triazol, isoxazol, isotiazol, y tiadiazol, en la que cada pirazol,oxadiazol, triazol, isoxazol, isotiazol, y tiadiazol, está insustituido o sustituido con de uno a tres sustituyentes que se seleccionan a partir de R6 y R7; R5 se selecciona a partir de: hidrogeno, alquilo C1-10, halogeno, -CN, -CF3, -OCF3, -C(O)alquilo C1-4, -C(O)O-alquilo C1-4, -O-alquilo C1-4, y -S-alquilo C1-4; R6 se selecciona a partir de: hidrogeno, alquilo C1-10, halogeno, -CN, -C(O)alquilo C1-6, -O-alquilo C1-6, -OCF3, y -S-alquilo C1-6; R7 se selecciona a partir de H, alquiloc1-6, y C(O)alquilo C1-10; Ra se selecciono a partir de: alquilo c1-6, y cicloalquilo C3-7, en la que cada alquilo y cicloalquilo está insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH,-alquilo C1-6, y halogeno, Rb se selecciona a partir de H, alquilo C1-6, y fenilo, en la que cada alquilo y fenilo está insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH, -alquilo C1-6,y halogeno, Rc se selecciona a partir de alquilo C1-6, y fenilo, en la que cada alquilo y fenilo está insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH, -alquilo C1-6, y halogeno; y Rdse selecciona a partir de: H, y alquilo C1-6, en la que cada alquilo está insustituido o sustituido con de uno a cuatro sustituyentes que se seleccionan independientemente a partir de -OH, -alquilo C1-6, y halogeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92285107P | 2007-04-11 | 2007-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065983A1 true AR065983A1 (es) | 2009-07-15 |
Family
ID=39473766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101449A AR065983A1 (es) | 2007-04-11 | 2008-04-08 | Derivados de furo [2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080269279A1 (es) |
| EP (1) | EP2146997B1 (es) |
| JP (1) | JP2010523665A (es) |
| AR (1) | AR065983A1 (es) |
| AT (1) | ATE487723T1 (es) |
| AU (1) | AU2008239755A1 (es) |
| CA (1) | CA2683586A1 (es) |
| CL (1) | CL2008001007A1 (es) |
| DE (1) | DE602008003432D1 (es) |
| PE (1) | PE20090142A1 (es) |
| TW (1) | TW200906398A (es) |
| WO (1) | WO2008127585A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| WO2011137012A1 (en) * | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| ES2916833T3 (es) * | 2015-10-09 | 2022-07-06 | Mitsui Chemicals Agro Inc | Compuestos de piridona, y fungicidas agrícolas y hortícolas que contienen dichos compuestos como principio activo |
| KR20240023691A (ko) | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1454864A (en) * | 1974-03-05 | 1976-11-03 | Wyeth John & Brother Ltd | Thioureas |
| US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| US5338740A (en) * | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| US5489685A (en) * | 1994-05-12 | 1996-02-06 | Merck & Co., Ltd. | Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| US5656638A (en) * | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5703116A (en) * | 1995-04-18 | 1997-12-30 | Geron Corporation | Telomerase Inhibitors |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| US7774473B2 (en) * | 2002-07-31 | 2010-08-10 | Oracle America, Inc. | System and method for sticky routing of requests within a server farm |
| JP4667867B2 (ja) * | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ［２，３−ｂ］ピリジン誘導体 |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| TW200602314A (en) * | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
-
2008
- 2008-04-04 PE PE2008000617A patent/PE20090142A1/es not_active Application Discontinuation
- 2008-04-07 WO PCT/US2008/004533 patent/WO2008127585A1/en active Application Filing
- 2008-04-07 US US12/082,013 patent/US20080269279A1/en not_active Abandoned
- 2008-04-07 AU AU2008239755A patent/AU2008239755A1/en not_active Abandoned
- 2008-04-07 CA CA002683586A patent/CA2683586A1/en not_active Abandoned
- 2008-04-07 EP EP08742647A patent/EP2146997B1/en not_active Not-in-force
- 2008-04-07 JP JP2010503035A patent/JP2010523665A/ja not_active Withdrawn
- 2008-04-07 AT AT08742647T patent/ATE487723T1/de not_active IP Right Cessation
- 2008-04-07 DE DE602008003432T patent/DE602008003432D1/de active Active
- 2008-04-08 TW TW097112669A patent/TW200906398A/zh unknown
- 2008-04-08 AR ARP080101449A patent/AR065983A1/es not_active Application Discontinuation
- 2008-04-09 CL CL200801007A patent/CL2008001007A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2683586A1 (en) | 2008-10-23 |
| TW200906398A (en) | 2009-02-16 |
| US20080269279A1 (en) | 2008-10-30 |
| CL2008001007A1 (es) | 2008-10-17 |
| EP2146997A1 (en) | 2010-01-27 |
| ATE487723T1 (de) | 2010-11-15 |
| AU2008239755A8 (en) | 2009-11-12 |
| PE20090142A1 (es) | 2009-02-19 |
| WO2008127585A1 (en) | 2008-10-23 |
| DE602008003432D1 (de) | 2010-12-23 |
| AU2008239755A1 (en) | 2008-10-23 |
| EP2146997B1 (en) | 2010-11-10 |
| JP2010523665A (ja) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110421A1 (es) | Derivados de pirazol como inhibidores de malt1 | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| ES2616477T3 (es) | Heterociclaminas como inhibidores de pi3k | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR076908A1 (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR080754A1 (es) | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 | |
| PE20081776A1 (es) | Moduladores 2-aminopirimidina del receptor histamina h4 | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR078168A1 (es) | Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119 | |
| AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
| AR110405A1 (es) | Compuestos | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR065983A1 (es) | Derivados de furo [2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| PE20080855A1 (es) | Derivados de pirazina-2-carboxamida | |
| PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |